Last reviewed · How we verify
Corticosteroid boluses Methylprednisolone
Methylprednisolone is a synthetic corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
Methylprednisolone is a synthetic corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Acute exacerbations of multiple sclerosis, Severe autoimmune and inflammatory conditions requiring rapid immunosuppression, Acute transplant rejection.
At a glance
| Generic name | Corticosteroid boluses Methylprednisolone |
|---|---|
| Sponsor | Hospices Civils de Lyon |
| Drug class | Corticosteroid (glucocorticoid) |
| Target | Glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Rheumatology / Neurology |
| Phase | Phase 3 |
Mechanism of action
Methylprednisolone acts as a glucocorticoid receptor agonist, translocating to the nucleus to modulate gene expression of inflammatory mediators. When administered as boluses (high-dose pulses), it rapidly dampens immune cell activation, reduces vascular permeability, and decreases production of cytokines and chemokines. This makes it effective for acute inflammatory and autoimmune conditions requiring rapid immunosuppression.
Approved indications
- Acute exacerbations of multiple sclerosis
- Severe autoimmune and inflammatory conditions requiring rapid immunosuppression
- Acute transplant rejection
Common side effects
- Hyperglycemia
- Hypertension
- Insomnia
- Mood changes (agitation, anxiety)
- Infection risk (immunosuppression)
- Osteoporosis (with chronic use)
- Gastrointestinal upset
Key clinical trials
- 3-month Screening Biopsy to Optimize the Immunosuppression in Renal Transplantation (PHASE3)
- Ultra Low Doses of Therapy With Radiation Applicated to COVID-19 (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: